Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 8/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392291 | 0.93 | BDKRB1 (0.48) | BDKRB1DRD2DRD4DRD3STS | |
| SCHEMBL5393651 | 0.90 | BDKRB1 (0.47) | BDKRB1DRD2DRD4DRD3STS | |
| SCHEMBL5390404 | 0.89 | BDKRB1 (0.41) | BDKRB1DRD2DRD4DRD3STS | |
| SCHEMBL5195761 | 0.89 | BDKRB1 (0.39) | BDKRB1DRD2DRD4DRD3 | |
| SCHEMBL5377553 | 0.89 | BDKRB1 (0.43) | BDKRB1DRD2DRD4DRD3STS | |
| SCHEMBL5402637 | 0.87 | BDKRB1 (0.38) | BDKRB1DRD2STS | |
| SCHEMBL5216063 | 0.82 | BDKRB1 (0.44) | BDKRB1DRD2DRD4DRD3STS | |
| SCHEMBL5381885 | 0.81 | BDKRB1 (0.36) | BDKRB1STS | |
| SCHEMBL5396927 | 0.80 | BDKRB1 (0.46) | BDKRB1NR1H4 | |
| SCHEMBL5251466 | 0.80 | BDKRB1 (0.48) | BDKRB1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | BDKRB1 1/4885DRD2 797/4885DRD4 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.